Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.
Vinge has advised Smart Eye Aktiebolag (First North Growth Market) in connection with its fully secured rights issue which provided Smart Eye with MSEK 324 before transaction costs. The issue was fully subscribed and no guarantee commitments had to be utilised.
Vinge has advised Danske Bank A/S, Danmark, Sverige Filial in connection with the signing of a new SEK 750 million credit facility for Svenska Retursystem Aktiebolag.
Vinge advises Biotage AB (publ) (“Biotage”) in connection with its acquisition of Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma Biosciences (“Gamma”), a life sciences tools platform created and controlled by KKR.
Vinge has advised Byggfakta Group (Nasdaq Stockholm) in conjunction with the acquisition of approximately 73 per cent of the shares in 4CastGroup AS with the subsidiaries Prognosesenteret AS in Norway and Prognoscentret AB in Sweden, which are leading in the Nordic region in the field of market analyses and forecasts for the building and construction market.
Vinge has advised Neobo Fastigheter AB (publ) (”Neobo”) in connection with the listing of Neobo’s shares on Nasdaq First North Premier. The company description was published on 6 February 2023 and the first day of trading on Nasdaq First North Premier was on 10 February 2023.
AmSpec Group, Inc., together with its subsidiaries (“AmSpec”), is a multinational group of companies within inspection, analysis and testing of products in the energy- and agricultural industries.
Vinge has advised Veeco Instruments Inc. ("Veeco"), a US company listed on NASDAQ, in its acquisition of Epiluvac AB, a privately held manufacturer of chemical vapor deposition epitaxy systems that enable advanced silicon carbide (“SiC”) applications in the electric vehicle market. Epiluvac, based in Lund, Sweden, was founded in 2013 by a highly experienced team in SiC.
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.
Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with the distribution of the shares in Neobo Fastigheter AB (publ) (”Neobo”) to the A and B shareholders in SBB. The resolution on the distribution was adopted at the Extraordinary General Meeting of SBB on 21 December 2022 and the distribution was carried out on 30 December 2022.
Vinge has advised Litorina’s portfolio company Leos Lekland in conjunction with its merger with the Finnish HopLop, with CapMan Special Situations I as majority owner. The new group will be the leader in Europe and initially manage 68 indoor play areas in Sweden, Finland, Norway, Denmark and Germany.
Vinge has advised Sandvik AB (publ) and Sandvik Treasury AB (publ) in connection with the entry into of a EUR 500 million loan agreement with the European Investment Bank (EIB). The loan will support Sandvik’s investments in research and development (R&D), which include advanced solutions in component manufacturing as well as solutions for electrification and automation in mining and infrastructure.
